Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with ...

The consensus estimate for Q4 2025 revenue is $1.36 million, and the earnings are expected to come in at $0.05 per share. The full-year 2025 revenue is expected to be $6.77 million, and the earnings ...

Strategic leadership changes -- Eran Ophir became CEO in September 2025, with Anat Cohen-Dayag transitioning to Executive Chair to enhance operational focus and strategic continuity.

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will ...

HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ...

Compugen’s anti-PVRIG antibody showed early promise in a small phase 1 study, curbing tumor growth in more than two-thirds of patients with various solid tumors who had exhausted all other treatment ...

HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...

Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer ...

The announcement from Compugen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor ...

COM902 and COM701 will allow the Company to clinically evaluate the dual blockade of PVRIG and TIGIT inhibitory pathways in the DNAM axis HOLON, Israel, April 6, 2020 /PRNewswire/ -- Compugen Ltd.